Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Acurx Pharmaceuticals, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −1 vs. Q4 2022
- Shares held
- 538.6K
- −778.9K (−59.1%) vs. Q4 2022
- Total value
- $1.86M
- −$3.39M (−64.5%) vs. Q4 2022
- New holders
- 1
- 4 more added
- Sold out
- 2
- 3 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $185.5K |
| Q1 2026 | 21 | $674.2K |
| Q4 2025 | 18 | $345.2K |
| Q3 2025 | 16 | $241.5K |
| Q2 2025 | 32 | $1.33M |
| Q1 2025 | 24 | $1.36M |
| Q4 2024 | 26 | $1.15M |
| Q3 2024 | 22 | $2.41M |
| Q2 2024 | 25 | $2.71M |
| Q1 2024 | 26 | $3.05M |
| Q4 2023 | 23 | $4.18M |
| Q3 2023 | 18 | $1.32M |
| Q2 2023 | 13 | $3.94M |
| Q1 2023 | 12 | $1.86M |
| Q4 2022 | 14 | $5.27M |
| Q3 2022 | 14 | $4.66M |
| Q2 2022 | 12 | $1.43M |
| Q1 2022 | 9 | $1.15M |
| Q4 2021 | 11 | $455.3K |
| Q3 2021 | 8 | $332.0K |
| Q2 2021 | 3 | $163.0K |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Acurx Pharmaceuticals, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 280,000 | $968.8K | 0.02% | −600,000−68.2% | Reduced |
| Vanguard Group Inc | 89,485 | $309.6K | 0.00% | +89,485 | New |
| Geode Capital Management, LLC | 77,283 | $267.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 22,051 | $76.0K | 0.00% | −7,045−24.2% | Reduced |
| TD Waterhouse Canada Inc. | 18,656 | $63.4K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 16,161 | $55.9K | 0.00% | +522+3.3% | Added |
| Advisor Group Holdings, Inc. | 16,000 | $55.4K | 0.00% | +4,000+33.3% | Added |
| Tocqueville Asset Management L.P. | 10,100 | $34.9K | 0.00% | 00.0% | Unchanged |
| Belpointe Asset Management LLC | 3,000 | $10.4K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,904 | $10.0K | 0.00% | +168+6.1% | Added |
| Tower Research Capital LLC (TRC) | 2,890 | $10.0K | 0.00% | −5−0.2% | Reduced |
| Wells Fargo & Company | 62 | $215 | 0.00% | +1+1.6% | Added |
| Draper Asset Management, LLC | 0 | $0 | 0.00% | −266,025−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Semmax Financial Advisors Inc. | – | – | – | – | Not filed |